- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02181855
Effect of Full-thickness Gastroplication With the GERD-X System on Atypical Gastro-esophageal-reflux-symptoms
January 28, 2015 updated by: Technical University of Munich
Effect of Full-thickness Gastroplication With the GERD-X System on Atypical Gastro-esophageal-reflux-symptoms.
Patients with atypical symptoms of objectified gastroesophageal reflux disease will be treated by full-thickness gastroplication and the effect of this intervention will be measured by questionnaires and clinical diagnostics (for example pH/MII).
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
23
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Linz, Austria, 4010
- Not yet recruiting
- Krankenhaus der Barmherzigen Schwestern Linz, Klinik für Allgemein- und Viszeralchirurgie
-
Contact:
- Georg Spaun, PD Dr. med.
- Phone Number: 7300 +43 732-7677-
- Email: georg.spaun@bhs.at
-
Contact:
- Oliver Koch, PD Dr. med.
- Phone Number: 7300 +43 732-7677-
- Email: oliver.owen.koch@gmail.com
-
Principal Investigator:
- Georg Spaun, PD Dr. med.
-
Principal Investigator:
- Oliver Koch, PD Dr. med.
-
-
-
-
-
Ludwigsburg, Germany, 71640
- Recruiting
- Klinikum Ludwigsburg, Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie, Diabetologie und Infektiologie
-
Contact:
- Karel Caca, Prof. Dr. med.
- Phone Number: 67200 +49 7141-99-
- Email: karel.caca@kliniken-lb.de
-
Contact:
- Arthur Schmidt, Dr. med.
- Phone Number: 67200 +49 7141-99-
- Email: Arthur.Schmidt@kliniken-lb.de
-
Principal Investigator:
- Carel Kaka, Prof. Dr. med.
-
Principal Investigator:
- Arthur Schmidt, Dr. med.
-
-
Bavaria
-
München, Bavaria, Germany, 81675
- Recruiting
- Klinikum rechts der Isar der Technischen Universität München, II. Med. Klinik und Poliklinik
-
Contact:
- Simon Nennstiel, Dr. med.
- Phone Number: 2251 +49 89-4140
- Email: simon.nennstiel@lrz.tum.de
-
Contact:
- Monther Bajbouj, PD Dr. med.
- Phone Number: 2251 +49 89-4140-
- Email: monther.bajbouj@lrz.tum.de
-
Principal Investigator:
- Monther Bajbouj, PD Dr. med.
-
Principal Investigator:
- Simon Nennstiel, Dr. med.
-
Sub-Investigator:
- Stefan von Delius, PD Dr. med.
-
München, Bavaria, Germany, 81675
- Recruiting
- Klinikum rechts der Isar der Technischen Universität München, Klinik und Poliklinik für Chirurgie
-
Contact:
- Hubertus Feußner, Prof. Dr. med.
- Phone Number: 2139 +49 89-4140-
- Email: hubertus.feussner@tum.de
-
Principal Investigator:
- Hubertus Feußner, Prof. Dr. med.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age between 18 years and 80 years
- symptomatic, objectified reflux disease (atypical symptoms - Montreal-classification)
Exclusion Criteria:
- Rejection of study-participation,
- Pregnancy
- negative pH-metry / impedance monitoring (non-objectified reflux)
- hiatal hernia bigger than 2 cm or gastroesophageal junction > Hill IV classification
- different potential reasons for atypical symptoms like heterotopic gastric mukosa in the cervikal esophagus
- Achalasia, esophageal spasm
- Presence of contraindications for the interventions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Atypical GERD syptoms treated with GERD-X
Patients treated by means of full-thickness gastroplication
|
Endoscopic full-thickness gastroplication wit the GERD-X device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Reflux Symptom index
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Monther Bajbouj, PD Dr. med., Klinikum rechts der Isar, II. Med
- Principal Investigator: Simon Nennstiel, Dr. med., Klinikum rechts der Isar, II. Med
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2014
Primary Completion (Anticipated)
December 1, 2015
Study Registration Dates
First Submitted
July 2, 2014
First Submitted That Met QC Criteria
July 3, 2014
First Posted (Estimate)
July 4, 2014
Study Record Updates
Last Update Posted (Estimate)
January 29, 2015
Last Update Submitted That Met QC Criteria
January 28, 2015
Last Verified
January 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- atyGERD-X
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atypical Gastroesophageal Reflux Symptoms
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
Medical College of WisconsinNot yet recruitingGastroesophageal Reflux Disease | Refractory Gastroesophageal Reflux DiseaseUnited States
-
Onconic Therapeutics Inc.Not yet recruitingNon-erosive Gastroesophageal Reflux Disease
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingGastroesophageal Reflux Disease (GERD) | Non-Erosive Gastro-Esophageal Reflux DiseaseRussia
-
Ying ZhuNot yet recruitingGastroesophageal Reflux Disease (GERD)China
-
Daewon Pharmaceutical Co., Ltd.CompletedGERD (Gastroesophageal Reflux Disease)South Korea
-
Ezisurg Medical Co. Ltd.University Hospital, MontpellierCompletedGastroesophageal Reflux Disease (GERD)France
-
Cinclus Pharma Holding ABWithdrawn
Clinical Trials on Full-thickness gastroplication (GERD-X)
-
General Public Hospital Zell am SeeUnknownGastroesophageal Reflux DiseaseAustria
-
Indiana UniversityRecruiting
-
Semmelweis UniversityInstitut Straumann AG; Geistlich Pharma AG; Dicomlab Kft.Recruiting
-
NDO Surgical, Inc.Terminated
-
Assistance Publique - Hôpitaux de ParisTerminated
-
NDO Surgical, Inc.Terminated
-
NDO Surgical, Inc.CompletedGastroesophageal Reflux Disease (GERD)United States, Canada
-
NDO Surgical, Inc.Completed
-
Kliniken Ludwigsburg-Bietigheim gGmbHOvesco Endoscopy AGUnknownColorectal Adenomas | Submucosal TumorsGermany
-
Chinese University of Hong KongRecruiting